Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Detailed price information for Tempest Therapeutics Inc (TPST-Q) from The Globe and Mail including charting and trades.